Other News

MedHub Announces completion of its pivotal multi-center validation study and raises $1 million in new financing

TEL AVIV, Israel, Feb. 8, 2022 /PRNewswire/ — MedHub, a privately held medical device company focused on improving and simplifying cardiac care by replacing risky and costly invasive procedures with AI image-based tools, today announced that it has successfully secured $1 million bringing the total sum raised to $4.2 million. The round was led by […]

MediLynx Cardiac Monitoring Partners with National Heart, Lung and Blood Institute & National Institutes of Health on Study of Efficacy of Mobile Cardiac Monitoring for Patients

PLANO, Texas, Feb. 8, 2022 /PRNewswire/ — MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics™), a national remote monitoring provider and technology leader in deep learning artificial intelligence, today announced a groundbreaking partnership with the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN) to participate […]

Leqvio® Therapy to Lower Cholesterol Approved by FDA, IVX Health Now Accepting New Leqvio Patients

NASHVILLE, Tenn., Feb. 8, 2022 /PRNewswire/ — IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions, announced today the expansion of its injection formulary with the addition of Leqvio® (inclisiran), a new FDA-approved therapy by Novartis Pharmaceuticals Corporation indicated for the treatment of adult patients with clinical atherosclerotic cardiovascular disease (ASCVD) […]

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

THOUSAND OAKS, Calif., Feb. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include: For the fourth quarter, total revenues increased 3% to $6.8 billion in comparison to the fourth quarter of 2020, driven by increased Other Revenue […]

CereVasc Receives FDA IDE Approval to Begin Initial Clinical Study of the eShunt® System for Patients with Normal Pressure Hydrocephalus

BOSTON, Feb. 8, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt System in patients […]

Route 92 Medical® Announces First Patient Enrollment in the SUMMIT MAX Pivotal Clinical Trial for the Monopoint® Reperfusion System

SAN MATEO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a private medical technology company dedicated to becoming the performance leader in acute ischemic stroke intervention, today announced the first patient enrollment in its SUMMIT MAX clinical trial. SUMMIT MAX is a randomized, controlled, multi-center trial to […]

Neovasc Announces German Reimbursement Renewal and Commercial Progress

VANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022.  […]

Providers Rank Fujifilm “Best in KLAS” for Three Synapse® Enterprise Imaging Solutions

Fujifilm’s Synapse® Vendor Neutral Archive (VNA) ranked #1 for the third consecutive year. Lexington, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) — February 8, 2022, Lexington, Mass. – FUJIFILM Healthcare Americas Corporation, a leading provider of enterprise imaging and informatics solutions, has ranked #1 in KLAS Research’s 2022 ‘Best in KLAS’ report for Fujifilm’s Synapse VNA and Synapse Cardiology […]

AtriCure Publishes Inaugural ESG Report

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and Governance (ESG) report highlighting the company’s corporate responsibility and sustainability initiatives. AtriCure’s 2021 ESG Report showcases several […]

Pfizer Reports Fourth-Quarter and Full-Year 2021 Results

Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billion Fourth-Quarter 2021 Revenues of $23.8 Billion, Reflecting 106% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Declined 2% Operationally Driven Primarily by the Impact of Fewer Selling Days […]